• 1. Exciplex emission from the mixed dimer of naphthalene and 2-cyanonaphthalene in a supersonic jet
  Aloke Das,K. K. Mahato,Chayan K. Nandi,Tapas Chakraborty,Shridhar R. Gadre,Nikhil A. Gokhale Phys. Chem. Chem. Phys., 2002,4, 2162-2168
• 2. Excellent mechanical performance and enhanced dielectric properties of OBC/SiO2 elastomeric nanocomposites: effect of dispersion of the SiO2 nanoparticles?
  Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305
• 3. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293
• 4. Fe3O4 nanosphere@microporous organic networks: enhanced anode performances in lithium ion batteries through carbonization?
  Byungho Lim,Jaewon Jin,Jin Yoo,Seung Yong Han,Kyeongyeol Kim,Sungah Kang,Nojin Park,Sang Moon Lee,Hae Jin Kim,Seung Uk Son Chem. Commun., 2014,50, 7723-7726
• 5. Fe3O4@PANI: a magnetic polyaniline nanomaterial for highly efficient and handy enrichment of intact N-glycopeptides??
  Zhizhen Lai,Mo Zhang,Jinyu Zhou,Tianjing Chen,Dan Li,Xuejing Shen,Jia Liu,Jiang Zhou,Zhili Li Analyst, 2021,146, 4261-4267

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Phenethylamines

Professional Introduction to 2-(3,5-Dichlorophenyl)ethanamine (CAS No. 67851-51-8)

2-(3,5-Dichlorophenyl)ethanamine, chemically designated as N-(3,5-dichlorophenyl)ethanamine, is a significant compound in the realm of pharmaceutical and chemical research. This compound, identified by its CAS number 67851-51-8, has garnered attention due to its structural uniqueness and potential applications in the development of novel therapeutic agents. The presence of two chlorine atoms at the 3rd and 5th positions on the phenyl ring introduces a unique electronic and steric environment, making it a valuable scaffold for further chemical modifications and biological evaluations.

The molecular structure of 2-(3,5-Dichlorophenyl)ethanamine consists of an ethylamine side chain attached to a dichlorinated phenyl ring. This configuration allows for diverse interactions with biological targets, including enzymes and receptors, which are pivotal in drug design. The dichlorophenyl moiety enhances lipophilicity, a critical factor in drug bioavailability and membrane permeability. Such properties make it an attractive candidate for further exploration in medicinal chemistry.

In recent years, there has been a surge in research focused on developing small-molecule inhibitors for various diseases. Among these, compounds with aromatic rings substituted by halogens have shown promise in targeting enzymes involved in metabolic pathways. For instance, studies have highlighted the potential of dichlorophenyl derivatives in inhibiting kinases and other enzyme targets relevant to cancer therapy. The amine group in 2-(3,5-Dichlorophenyl)ethanamine provides a nucleophilic site for covalent bond formation with biological targets, enhancing binding affinity and selectivity.

One of the most compelling aspects of 2-(3,5-Dichlorophenyl)ethanamine is its versatility in serving as a precursor for more complex molecules. Researchers have leveraged this compound to synthesize derivatives with enhanced pharmacological properties. For example, by introducing additional functional groups or altering the substitution pattern on the phenyl ring, scientists can fine-tune the compound's activity against specific biological targets. This flexibility underscores its importance as a building block in drug discovery pipelines.

The synthesis of 2-(3,5-Dichlorophenyl)ethanamine involves multi-step organic reactions that require precise control over reaction conditions. Typically, it is prepared through nucleophilic aromatic substitution or reductive amination reactions. The dichlorophenyl group must be carefully handled to prevent unwanted side reactions, such as over-chlorination or dehalogenation. Advanced synthetic techniques, including catalytic hydrogenation and palladium-catalyzed cross-coupling reactions, have been employed to improve yield and purity.

The pharmacological evaluation of 2-(3,5-Dichlorophenyl)ethanamine has revealed intriguing properties that warrant further investigation. Preclinical studies have demonstrated its potential as an inhibitor of certain enzymes implicated in inflammatory diseases and neurodegenerative disorders. The compound's ability to modulate enzyme activity without significant off-target effects makes it an attractive candidate for further development into a therapeutic agent. Additionally, its structural features suggest potential applications in treating infectious diseases by targeting bacterial or viral enzymes.

In the context of computational chemistry and drug design, 2-(3,5-Dichlorophenyl)ethanamine serves as a valuable scaffold for virtual screening and molecular docking studies. By integrating this compound into computational models, researchers can predict its interactions with biological targets at an atomic level. Such simulations have accelerated the discovery process by identifying promising lead compounds that can be optimized further through experimental validation.

The environmental impact of synthesizing and handling 2-(3,5-Dichlorophenyl)ethanamine is another critical consideration. Efforts are underway to develop greener synthetic routes that minimize waste generation and reduce reliance on hazardous reagents. Solvent-free reactions and catalytic methods are being explored to enhance sustainability while maintaining high yields and purity standards. These advancements align with global initiatives to promote environmentally responsible chemical synthesis.

The future prospects for 2-(3,5-Dichlorophenyl)ethanamine are promising given its unique structural features and potential therapeutic applications. Ongoing research aims to expand its utility by exploring novel synthetic pathways and evaluating its efficacy in preclinical models. Collaborative efforts between academic institutions and pharmaceutical companies will be essential in translating laboratory findings into clinical trials and ultimately into new treatments for human diseases.

• 14573-23-0(2,6-Dichlorophenethylamine)
• 38171-31-2(N-Methyl-4-chlorophenethylamine)
• 4806-79-5(2-(4-Chlorophenyl)propan-1-amine Hydrochloride)
• 52516-13-9(2,4-Dichlorophenethylamine)
• 89042-13-7(2-(3-Chloro-phenyl)-ethylamine hydrochloride)
• 13078-79-0(2-(3-Chlorophenyl)ethylamine)
• 156-41-2(2-(4-Chlorophenyl)ethylamine)
• 2492-83-3(2-(4-Chlorophenyl)Ethylamine Hyrochloride)
• 21581-45-3(3,4-Dichlorophenethylamine)
• 75425-55-7(2-(4-Chlorophenyl)propan-1-amine hydrochloride)